TY - JOUR T1 - Short-term versus 6-week prednisone in the treatment of subacute thyroiditis: a randomized controlled trial JF - medRxiv DO - 10.1101/2020.02.15.20023283 SP - 2020.02.15.20023283 AU - Lian Duan AU - Xiaoli Feng AU - Rui Zhang AU - Xiaojuan Tan AU - Xiaoyan Xiang AU - Rufei Shen AU - Hongting Zheng Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/20/2020.02.15.20023283.abstract N2 - Background Moderate-to-severe subacute thyroiditis is commonly treated with 6-8 weeks glucocorticoids; however, no studies have described short-term prednisone treatment for subacute thyroiditis. We evaluated the efficacy of this treatment for subacute thyroiditis.Methods This was a 24-week, prospective, single-blind, randomized controlled study. Patients aged 18-70 years with subacute thyroiditis were hospitalized from August 2013 to December 2014. Patients with moderate-to-severe symptoms were randomized to receive either 30 mg/d prednisone for 1 week and then switched to 1 week of nonsteroidal anti-inflammatory drugs or 6 weeks of prednisone. The primary endpoints were the differences in efficacy at the end of treatment between two groups. Secondary endpoints included differences between the two groups in parameters of side effects at withdrawal and thyroid function at weeks 6, 12, 24.Results Of 96 patients screened, 52 subjects were randomized and 50 completed the study. Efficacy and recurrence rates were not significantly different at withdrawal in both groups (P=0.65). Parathyroid hormone (28.8 vs 38.9 pg/ml, p=0.011) and mean systolic blood pressure (113.9 vs 122.4 mmHg, p=0.023) were significantly lower in the experimental group than in the control group at discontinuation. No significant differences were observed in other secondary endpoints at withdrawal and in thyroid function at the 6th, 12th and 24th week during the follow-up time between the two groups.Conclusions Fewer side effects of glucocorticoids and similar efficacy and recurrence rates were observed with short-term prednisone compared with those with 6-week treatment for subacute thyroiditis. Short-term prednisone with a better safety profile may be as one alternative strategy for ameliorating moderate-to-severe symptoms of subacute thyroiditis.Trial registration Trial registration number NCT01837433. Registered with Clinicaltrials.gov on 23 April 2013Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01837433Clinical Protocols https://register.clinicaltrials.gov/prs/app/action/LoginUser?ts=1&cx=-jg9qo4 Funding StatementThis work was supported by the grant from Clinical Research Project of Xinqiao Hospital of Third Military Medical University (grant numbers Yclkt-201421), Key Laboratory Incubation Project of the Third Affiliated Hospital of Chongqing Medical University (Jie er Hospital) (grant numbers KY19025) and High-level Medical Reserved Personnel Training Project of Chongqing (grant numbers RC18004). The funding source had no influence on the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly available due to individual privacy but are available from the corresponding author on reasonable request. ER -